Patient-reported improvements from use of IMC-2 alone and IMC-2 and Paxlovid® in a Long COVID cohort: a case series

William L. Pridgen, David Putrino · 2026

Read Patient-reported improvements from use of IMC-2 alone and IMC-2 and Paxlovid® in a Long COVID cohort: a case series by William L. Pridgen, David Putrino (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12812670.txt.

Description

William Pridgen and David Putrino report patient rated gains from long antiviral courses in long COVID, in a case series whose head is dated 2025. No approved treatment exists for the condition; lingering virus and revived herpesviruses are suspect drivers. Twenty seven patients were approached at one clinic; twenty four finished a 120 day course of one antiviral, half with a second drug, Paxlovid, added for the first fifteen days.

Both groups felt less fatigue, but the two drug group improved far more on global change and scale scores, about fifty five percent more fatigue relief on one measure. Brain fog and autonomic symptoms were also tracked.

Catalog record

CREATORWilliam L. Pridgen, David Putrino
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE22 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC12812670

Browse the full library · About the Tower of Babel